The clinical evaluation of a patient with suspected benign prostatic hyperplasia is aimed at confirming the diagnosis, assessing the severity of symptoms and their impact on quality of life, and ruling out other conditions that may cause similar symptoms, such as prostate cancer, urinary tract infection, or neurogenic bladder. A comprehensive evaluation includes a detailed medical history, a physical examination, and selected investigations.
Clinical Evaluation
The initial assessment of a patient with LUTS suggestive of BPH should include the following components:
- Medical History: A thorough history should be taken, focusing on the nature and duration of urinary symptoms. The use of a validated symptom scoring system, such as the International Prostate Symptom Score (IPSS), is recommended to quantify the severity of symptoms and their impact on the patient's quality of life. The history should also include a review of comorbidities, previous surgeries, and current medications that may affect lower urinary tract function.
- Physical Examination: A general physical examination should be performed, with a focus on the abdomen to assess for a palpable bladder, which may indicate urinary retention. A digital rectal examination (DRE) is essential to assess the size, consistency, and contour of the prostate, and to detect any nodules or induration that may be suspicious for prostate cancer.
- Urinalysis: A urinalysis should be performed to screen for evidence of urinary tract infection, hematuria, or other abnormalities.
- Prostate-Specific Antigen (PSA): A baseline serum PSA level should be considered in patients with a life expectancy of more than 10 years, as it can be useful for prostate cancer screening and for predicting the risk of BPH progression.
Management of BPH
The management of BPH is tailored to the individual patient, based on the severity of symptoms, the degree of bother, and the presence of complications. The treatment options range from conservative management to pharmacological therapy and surgical intervention.
| Management Strategy | Description | Indications |
|---|---|---|
| Watchful Waiting | Also known as active surveillance, this approach involves monitoring the patient's symptoms and clinical status without active treatment. Lifestyle modifications, such as fluid management and avoidance of bladder irritants, may be recommended. | Mild symptoms (IPSS < 8) with minimal bother and no complications. |
| Pharmacological Therapy | The use of medications to relieve symptoms and prevent disease progression. The main classes of drugs used are alpha-1 blockers and 5-alpha reductase inhibitors. | Moderate to severe symptoms (IPSS ≥ 8) without absolute indications for surgery. |
| Surgical Intervention | A variety of surgical procedures are available to remove or ablate the obstructing prostatic tissue. These range from minimally invasive techniques to more traditional open surgery. | Severe symptoms, failure of medical therapy, patient preference, or the presence of complications such as refractory urinary retention, recurrent urinary tract infections, bladder stones, or renal insufficiency due to BPH. |
The choice of treatment should be a shared decision between the patient and the clinician, taking into account the risks and benefits of each option, as well as the patient's preferences and values. The subsequent chapters will provide a more detailed discussion of the pharmacological and surgical management of BPH.